ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

tisotumab vedotin

Also written as “Tisotumab Vedotin”, “TIVDAK” and “Tisotumab Vedotin (HuMax-TF-ADC)”.

Its studies are mostly in Uterine Cervical Neoplasms · Ovarian Neoplasms · Colorectal Neoplasms · Neoplasm Metastasis, led by 3 companies.

Drug pageTisotumab vedotin: every studyAll 12 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Apr 15, 202511 company-led studies, 2 open or runningNext primary completion: Dec 13, 2028 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer92 open or runningphase 4since Apr 15, 2025Nov 14, 2013Dec 13, 2028phase 4 · NCT06952660
Genmabits history only10 open or runningphase 2since Mar 29, 2019Mar 29, 2019none ahead
Zai Labits history only10 open or runningphase 1since Apr 27, 2023Apr 27, 2023none ahead

Also a collaborator on its studies: Merck.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Pfizer only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Nov 14, 2013First study: phase 2 study in Ovarian NeoplasmsFirst studyNCT02001623 · 195 enrolled · United States, Belgium, Denmark and more
  2. Jun 9, 2015Named tisotumab vedotinINNProposed as its International Nonproprietary Name in WHO's List 113
  3. Sep 14, 2015Phase 2 study in Ovarian NeoplasmsNCT02552121 · 33 enrolled · United States, Belgium, Denmark and more
  4. Aug 8, 2017Phase 2 study in Ovarian NeoplasmsNCT03245736 · 5 enrolled · United States, United Kingdom
  5. Feb 8, 2018Phase 2 study in Uterine Cervical NeoplasmsNCT03438396 · 102 enrolled · United States, Belgium, Czechia and more
  6. Mar 8, 2018Phase 2 study in Colorectal NeoplasmsNCT03485209 · 350 enrolled · United States, Canada, France and more
  7. Aug 22, 2018Phase 2 study in Ovarian NeoplasmsNCT03657043 · 98 enrolled · United States, Belgium, Denmark and more
  8. Dec 13, 2018Phase 2 study in Uterine Cervical NeoplasmsNCT03786081 · 214 enrolled · United States, Belgium, Czechia and more
  9. Jan 4, 2021Phase 3 study in Uterine Cervical NeoplasmsNCT04697628 · 502 enrolled · United States, Argentina, Austria and more
  10. Apr 15, 2025Phase 4 study in Uterine Cervical NeoplasmsNCT06952660 · 100 planned · United States, Puerto Rico

Ahead

  1. Dec 13, 2028Primary completion: phase 4 study in Uterine Cervical NeoplasmsNCT06952660

TargetBeta

F3 →read by rule
“An antibody-drug conjugate (ADC) comprised of tisotumab, a monoclonal antibody against human tissue factor (TF) covalently coupled, via a protease-cleavable peptide linker, to monomethyl auristatin E (MMAE), an auristatin derivative and potent microtubule disrupting agent, ”NCIt, by rule
“Coagulation factor III binding agent”ChEMBL 37, by rule

Other programs on F3

ProgramCompanyFurthest phaseStudies
Anti-TF/TOP1i Antibody-drug Conjugate XNW28012ruleEvopoint Biosciencesphase 33
Anti-TF Antibody-drug Conjugate MRG004Arulelepu-biopharma-co-ltdphase 32
SHR-4375Jiangsu HengRui Medicinephase 22
Anti-TF/TOP1i Antibody-drug Conjugate XB371ruleExelixisphase 11
Anti-TF/Exatecan Antibody-drug Conjugate STRO-004rulesutro-biopharma-incphase 11

Studies

All 9 Pfizer leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06952660Uterine Cervical Neoplasms · United States, Puerto Rico4RecruitingDec 13, 2028100
NCT04697628Uterine Cervical Neoplasms · United States, Argentina, Austria and more3CompletedJul 24, 2023502
NCT03786081Uterine Cervical Neoplasms · United States, Belgium, Czechia and more2TerminatedMar 19, 2026214
NCT03657043Ovarian Neoplasms · United States, Belgium, Denmark and more2CompletedFeb 8, 202298
NCT03485209Colorectal Neoplasms · United States, Canada, France and more2Active, not recruitingMar 20, 2026350
NCT03438396Uterine Cervical Neoplasms · United States, Belgium, Czechia and more2CompletedFeb 6, 2020102
NCT03245736Ovarian Neoplasms · United States, United Kingdom2CompletedJan 10, 20195
NCT02552121Ovarian Neoplasms · United States, Belgium, Denmark and more2CompletedDec 13, 201733
NCT02001623Ovarian Neoplasms · United States, Belgium, Denmark and more2CompletedMay 2, 2019195

How it is read

Names in the registry

  • “tisotumab vedotin”, 5 entries
  • “Tisotumab Vedotin”, 3 entries
  • “TIVDAK”, 1 entry
  • “Tisotumab Vedotin (HuMax-TF-ADC)”, 1 entry
  • “Tisotumab vedotin (HuMax-TF-ADC)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.